Dr. Mark O’Hara of the Abramson Cancer Center discusses checkpoint inhibition in the context of pancreatic cancer in this presentation from the Abramson Cancer Center’s Immunology and Immunotherapy for Pancreatic Cancer Symposium. A clinician investigator, Dr. O’Hara offers and overview of checkpoint inhibition in its application to pancreatic adenocarcinoma, and in so doing illuminates the strategies moving to the forefront of the field, including combination therapies (e.g., gemcitabine/nivolumab/nab-paclitaxel) and regimens involving checkpoint inhibition and hypofractionated radiotherapy.
Enrolling Clinical Trials: Combination Chemotherapy / Immunotherapy for Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Dr. O’Hara’s physician profile
Connect with Dr. O’Hara on Doxmity